In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 102029-44-7, name is (R)-4-Benzyl-2-oxazolidinone, introducing its new discovery. Quality Control of (R)-4-Benzyl-2-oxazolidinone
PHARMACEUTICAL COMPOUNDS
The present invention relates to compounds of Formula (I) that are useful as inhibitors of the activity of the ubiquitin specific protease USP19. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in therapy.
We’ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 102029-44-7, and how the biochemistry of the body works.Quality Control of (R)-4-Benzyl-2-oxazolidinone
Reference:
Oxazolidine – Wikipedia,
Oxazolidine | C3H1605NO – PubChem